摘要
目的探讨冠状动脉粥样硬化性心脏病心律失常患者接受参松养心胶囊联合美托洛尔缓释片治疗的临床疗效。方法将2018年3月至2021年3月云浮市中医院收治的行美托洛尔缓释片治疗的23例冠状动脉粥样硬化性心脏病心律失常患者作为对照组,将同期收治的加用参松养心胶囊治疗的22例冠状动脉粥样硬化性心脏病心律失常患者作为观察组。比较两组心电图情况、心律失常变化、生化指标、血压水平及用药不良反应。结果治疗后,观察组心电图情况、心律失常变化、生化指标、血压水平优于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为13.64%,与对照组的21.74%比较,差异无统计学意义(P>0.05)。结论对冠状动脉粥样硬化性心脏病心律失常患者行参松养心胶囊+美托洛尔缓释片治疗,可有效改善其血脂、血压、心律失常症状,安全可靠。
Objective To analyze the clinical value of Shensong Yangxin Capsules combined with metoprolol sustained release tablets in the treatment of coronary heart disease patients with arrhythmia. Methods A total of 23 oronary heart disease patients with arrhythmia treated with metoprool sustained release tablets in Yunfu Hospital of Traditional Chinese Medicine from March 2018 to March 2021 were selected as the control group, and 22 oronary heart disease patients with arrhythmia treated with Shensong Yangxin capsule during the same period were selected as the observation group. ECG changes of arrhythmia, biochemical indexes,blood pressure and adverse drug reactions were compared between the two groups. Results After treatment, electrocardiogram,changes in arrhythmia, biochemical indexes and blood pressure in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.64%,which was not significantly different from 21.74% in the control group(P>0.05). Conclusion Shensong Yangxin Capsules and metoprolol sustained-release tablets can improve blood lipid, blood pressure and arrhythmia symptoms in coronary heart disease patients with arrhythmia, which is safe and reliable.
作者
赵毅
黄晓毅
ZHAO Yi;HUANG Xiao-Yi(Emergency Department,Yunfu Traditional Chinese Medicine Hospital,Yunfu 527300,China;Internal Medicine,Yunfu Traditional Chinese Medicine Hospital,Yunfu 527300,China)
出处
《中国药物经济学》
2022年第4期105-108,共4页
China Journal of Pharmaceutical Economics
